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Objectives: : The aim of this study is to highlight the importance of infections caused by members of the
genera Pseudallescheria/Scedosporium in HIV-positive patients.
Methods: We describe a case of a fatal scedosporiosis in a treatment-naı¨ve HIV patient and review all
previously reported cases of pseudallescheriosis/scedosporiosis from a search of the PubMed and
Deutsches Institut fu¨r Medizinische Dokumentation und Information (DIMDI) databases, applying the
terms ‘Pseudallescheria’, ‘Scedosporium’, ‘Allescheria’, ‘Monosporium’, ‘Petriellidium’, ‘boydii’, ‘proliﬁ-
cans’, ‘inﬂatum’, cross-referenced with ‘HIV’ and ‘AIDS’.
Results: Detection of Scedosporium and Pseudallescheria species has been reported in 22 HIV-positive
patients. Fourteen isolates belonged to the Pseudallescheria boydii complex and eight to Scedosporium
proliﬁcans. Invasive scedosporiosis (IS) was proven in 54.5% of the patients. Among them dissemination
was observed in 66.7%. Pseudallescheria/Scedosporium species were mainly isolated from male
individuals. Patients with proven IS showed CD4+ cell counts <100/ml and a higher co-infection rate
as compared to colonized patients. Patients with central nervous system (CNS) manifestations showed
CD4+ cell counts <50/ml. The mortality rate for patients with proven IS was 75% and was 100% for
patients with dissemination/CNS manifestations. The fatality rate for patients treated with antifungal
drugs plus surgery was lower compared to patients treated with antimycotic agents alone.
Conclusions: IS only occurred in HIV-positive patients with a strongly impaired immune system. The
survival rates of patients with advanced HIV disease and invasive scedosporiosis can be improved by
rapid diagnosis by biopsy and requires complex therapy with a combination of active antifungal drugs,
surgery and supportive immune augmentation.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Opportunistic mould infections have been considered an
infrequent complication of the HIV disease. Pulmonary aspergillo-
sis, listed as an opportunistic infection in HIV-infected adults and
adolescents by the Centers for Disease Control and Prevention
(CDC), is the most frequently diagnosed clinical feature in this risk
group.1 Reports on diseases caused by other species such as
zygomycetes and Pseudallescheria/Scedosporium species are rare.
Nevertheless, in retrospective autopsy studies, a substantial
number of fatal cases have been characterized following missed
ante-mortem diagnosis.2* Corresponding author. Tel.: +49 391 67 15859; fax: +49 391 67 13947.
E-mail address: ina.tammer@med.ovgu.de (I. Tammer).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.03.004In this article, we present a case of a cerebral infection due to
Scedosporium apiospermum in a patient with AIDS. Based on a
literature review we highlight the importance of this fungal
organism and related species, most frequently resistant to
amphotericin B, as causes of life-threatening infections in
individuals with advanced HIV disease.
2. Case report
A 31-year-old cachectic woman was admitted to a secondary
hospital because of progressive neurological symptoms without
further speciﬁcation (June 2007). Based on these symptoms, a
positive Toxoplasma antibody titer, and typical contrast-enhanced
lesions on magnetic resonance imaging (MRI), cerebral toxoplas-
mosis was suggested. Toxoplasmosis, cachexia, and pharyngeal
candidiasis were highly suggestive of an HIV infection, which wasses. Published by Elsevier Ltd. All rights reserved.
[(Figure_2)TD$FIG]
Figure 2. MRI at day 148 after ﬁrst admission. T2 transverse scan (Siemens
Magnetom Vision 1.5 T): new inhomogeneous, rounded mass of approximately
30 mm in diameter in the thalamus region and the left lateral basal ganglia with
perifocal edema and compression of the left lateral ventricle.
[(Figure_3)TD$FIG]
Figure 3. Histopathological examination. Necrotic and hemorrhagic brain tissue
derived from a brain biopsy, with demonstration of fungal elements using Grocott’s
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cell count of 31 cells/ml. Toxoplasma encephalitis (TE) was ﬁrst
treated with pyrimethamine, sulfadiazine, folic acid, and corti-
costeroids. Sulfadiazine was changed to clindamycin because of an
allergic skin reaction. Further diagnoses were cytomegalovirus
(CMV) reactivation diagnosed by CMV pp65 antigenemia, and
herpes simplex virus (HSV) reactivation conﬁrmed by positive PCR
from blood samples. The HSV infection was treated with
intravenous acyclovir therapy. Antiretroviral therapy (ART) was
initiated with abacavir/lamivudine and ritonavir-boosted ampre-
navir. The Candida albicans pharyngitis was treated with ﬂucona-
zole. The patient responded well to the therapy, resulting in a
decrease in the neurological symptoms, a reduction in the cerebral
foci, a decline in the HIV viral load to 117 copies/ml, and an
increase in the CD4+ count to 150/ml. On day 53 after admission
the patient was discharged from the hospital.
Three weeks later (day 74) the patient suffered from paresthe-
sia, paresis of the left side, and reduced taste sensation. She tended
to tilt but had no fever. At admission to the University Clinic
Magdeburg the following parameters were apparent: C-reactive
protein (CRP) 21.5 mg/l, leukocytes 12.9 109/l, CD4+ cell count 16
cells/ml, HIV viral load negative. MRI showed multiple foci
localized in the cerebrum, cerebellum, and in the basal ganglia
concordant with TE (Figure 1). Neurological symptoms were
considered as a side effect of the pyrimethamine therapy, resulting
in a dose reduction to 100 mg/day. ART and antiparasitic therapy
were continued as recommended. Clinical symptoms declined and
the woman was again discharged from hospital after 6 days
(day 79).
Three weeks later (day 94) the patient was re-admitted to the
hospital in a poor general condition (days 94–114). A detailed
examination showed paralysis of ocular movement, anisocoria,
ataxia, and hyperreﬂexia of the right side. Laboratory ﬁndings
showed a CD4+ cell count of 45/ml and an HIV viral load of 1120
copies/ml. The spinal ﬂuid showed <5 cells/ml, an increased
protein concentration of 746 mg/l (normal <450 mg/l), and a
massive disturbance of the blood–brain barrier. PCR testing of the
cerebrospinal ﬂuid (CSF) targeting HSV1/2-, CMV-, and Toxoplasma
gondii-speciﬁc genes, as well as screening tests for cryptococcal
antigen were negative. MRI was unchanged.
Four weeks later (day 146) the patient became stuporous and
had repeated convulsions. Her CD4+ count was 30/ml and HIV-1
RNA level was <40 copies/ml. Surprisingly, MRI revealed an[(Figure_1)TD$FIG]
Figure 1. MRI at day 75 after ﬁrst admission. T2 transverse scan (Siemens
MagnetomVision 1.5 T): multiple, rounded T2 hyperintense lesions on both sides of
the basal ganglia, compatible with cerebral toxoplasmosis.
methenamine silver stain; magniﬁcation of 200.additional mass measuring 4  4 cm in the right basal ganglia,
surrounded by a pronounced focal edema with collapse of the
ventricular system and a dislocation of the midline (Figure 2). A
stereotactic biopsy was performed. Microscopic examination from
the biopsy revealed tissue invasion (Figure 3) by branched,
septated hyphae (Figure 4). Thus, a combined antifungal therapy
with voriconazole and caspofungin was started. The course of
disease was further complicated by multi-organ failure. The
patient died on day 166. Permission for autopsy was denied.
2.1. Additional microbiological investigations
After 2 days of incubation at 37 8C a hyphomycete was
detectable from cultures of the brain biopsy on blood agar plates.
Macro- and microscopic features allowed a primary classiﬁcation
to the Pseudallescheria boydii complex. Based on sequence analysis
of the internal transcribed spacer (ITS) regions, the isolate was
identiﬁed as S. apiospermum. In vitro susceptibility testing revealed
minimum inhibitory concentrations (MICs) of 2mg/ml for
voriconazole and >16mg/ml for terbinaﬁne, and a minimal
[(Figure_4)TD$FIG]
Figure 4. Microbiological examination of the cerebral tissue with Gram staining,
showing branched septate hyphae (black arrows); magniﬁcation of 200.
I. Tammer et al. / International Journal of Infectious Diseases 15 (2011) e422–e429424effective concentration (MEC) of 0.5 mg/ml for caspofungin after
48 h of incubation. The isolate was deposited in the strain
collection of the Reference Laboratory of Mycology (Robert Koch
Institut (RKI), Berlin, Germany) under the number RKI 07-0571.
The sequence of the ITS regions was submitted to the NCBI
database and is available under GenBank accession number
HQ857581.
3. Methods
Because of several taxonomic changes we searched PubMed
and the Deutsches Institut fu¨r Medizinische Dokumentation und
Information (DIMDI) databases with the keywords:
‘Pseudallescheria’, ‘Scedosporium’, ‘Allescheria’, ‘Monospor-
ium’, ‘Petriellidium’, ‘boydii’, ‘proliﬁcans’, ‘inﬂatum’, cross-refer-
enced with ‘HIV’ and ‘AIDS’ in order to identify published cases of
Pseudallescheria/Scedosporium sp in HIV-infected persons.
A total of 24 additional cases, 22 in English and two in Spanish,
were identiﬁed as dealing with these pathogens in HIV-infected
people. The cases are listed in Table 1 in chronological order of the
year of publication. It must be noted that cases 12 and 15 describe
the same patient; this is also the case for cases 13 and 22. In
addition, cases 23 and 24 most likely refer to the same patient.
Hence these cases were summarized and counted as one case each.
Thus, a total of 22 case reports (including the case presented here)
were analyzed with regard to the following criteria: causative
species, clinical symptoms, manifestations of the disease, compli-
cations, concomitant diseases, laboratory ﬁndings, treatment
regime, and outcome, if available. Case 4 was only published as
an abstract.
Invasive infections due to these pathogens are entitled ‘invasive
scedosporiosis’ (IS). The caseswere deﬁned as ‘proven’ according to
the deﬁnitions of the European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative Group
and the National Institute of Allergy and Infectious Diseases
Mycoses Study Group (EORTC/MSG) consensus group.3 Patients
without signs and symptoms of clinical disease were categorized
as colonized, including those with fungus ball formation in pre-
existing cavities without demonstration of fungal elements in
diseased tissue.
The co-infection rate was calculated from the number of
diseases per case.
Based on new morphological, physiological, and molecular
data, the taxonomy of the fungi belonging to the genera
Pseudallescheria and Scedosporium has been revised in recent
years. P. boydii and S. apiospermum are now described as twodistinct species grouped into the newly deﬁned P. boydii
complex.4,5 Scedosporium proliﬁcans, formerly Scedosporium inﬂa-
tum, is distantly related to the P. boydii complex.
4. Results
Detection of Scedosporium and Pseudallescheria species has been
reported in 22 HIV-positive patients (Table 1).6–27 Fourteen
isolates belonged to the P. boydii complex and eight to S. proliﬁcans.
The most frequent portal of mould entry was the respiratory
tract (68.2%). In 86.7% of these cases the moulds were present in
the lung and in 13.3% in the paranasal sinuses. Three of the 22
patients (13.6%) suffered from otitis externa, whereas in four
patients (18.2%) the portal of entry remained unclear.
Invasive scedosporiosis was proven in 12 of the 22 patients
(proven IS; 54.5%). Ten patients met the criteria of ‘colonization’,
including three patients harboring a fungus ball in pulmonary
cavities. One patient with fungus ball formation developed
localized invasive infection, which was proven by histology. One
patient was co-colonized with two species, S. apiospermum and S.
proliﬁcans.
Proven invasive fungal infection was caused by members of the
P. boydii complex in eight patients and by S. proliﬁcans in four
patients.
IS was disseminated in eight of the 12 cases and was proven by
either fungemia or autopsy (66.7%). Five of these patients
developed central nervous system (CNS) manifestations.
Patients suffering from proven IS had 3.6 opportunistic diseases
per case, whereas patients who were only colonized showed a co-
infection rate of 2.0 on average (Table 2). Reactivation of members
of the family Herpesviridae and candidiasis were the most
frequently reported opportunistic infections. These were more
frequent in patients developing disseminated rather than localized
infections.
Co-isolation or infections due to Aspergillus species and
Pseudomonas aeruginosa infections were exclusively observed in
patients with proven IS.
The clinical outcome of the patients was fatal in 14 out of the 22
cases (63.6%, Table 1). Nine of all reported patients died as a result
of their fungal disease, leading to a mortality rate of 40.9% (Table
3).
Among the patientswith proven IS, 75% (n = 9/12) died,whereas
25% of the patients responded to therapy and survived (n = 3/12). In
one of these cases the cause of death remains unknown. All
survivors had localized infections caused by members of the P.
boydii complex. In contrast, all patients suffering from proven S.
proliﬁcans infections died.
CD4+ cell counts were available for 15 of the 22 patients (Table
2). Ten of the 15 patients had cell counts <50/ml (66.7%). In
addition, CD4+ counts <50/ml were reported from 62.5% of the
patients with proven IS and from 71.4% of the colonized patients.
The mean CD4+ cell count of the colonized patients was about
three times higher than that of patients with proven IS. All patients
with CNS manifestations showed CD4+ cell counts <50/ml.
The HIV viral load was reported in seven of 22 patients (31.8%).
Two of themwere colonized and ﬁve patients suffered fromproven
IS. Patients with proven localized infections had a ca. two-fold
higher viral load than colonized patients. Signiﬁcant data about
ART onset and virus resistances were not available.
ART was reported in detail in seven of 17 cases (41.2%) with
previously known HIV infection (Table 4). Five patients were ART-
naı¨ve because pseudallescheriosis/scedosporiosis was the ﬁrst
manifestation of the AIDS disease. Two of them died before ART
could be administered. No data were available for 10 cases.
Altogether seven of the cases were published in the era before
highly active antiretroviral therapy (HAART) was introduced. Four
Table 1
Pseudallescheria/Scedosporium infection in patients with HIV/AIDS: clinical characteristics
Case No. Ref. Pathogen Sex/age
(years)
Location and/or
diagnosis
Complications Culture specimen that
yielded moulds
Status of
fungal
infection
Outcome
1 Raffanti6 P. boydii M/53 Brain abscesses
Mitral valve
endocarditis
Dissemination,
multiple cerebral
emboli, coma,
respiratory failure
Blood cultures
Autopsy: mitral valve, CNS
Proven Death
2 Scherr7 P. boydii M/44 Lung Dissemination Transbronchial biopsy, BAL
Autopsy: kidney, lung
Proven Death
3 Wood8 S. proliﬁcans
S. apiospermum
M/50 Lung Sputum, BAL Colonization Survival
4 Garland9 S. proliﬁcans M/31 Left forearm
Lung abscess
Dissemination Biopsy of the nodule,
lung abscess,
heart, left forearm
Autopsy: lung, kidneys,
brain
Proven Death
5 Meyer10 P. boydii M/44 Ethmoid/
sphenoid sinuses
Destruction
of the right
maxillary bone,
respiratory
failure
Aspirate Colonization Death of
respiratory
failure
6 Hopwood11 S. proliﬁcans M/44 Lung Sputum, BAL Colonization Survival
7 Nenoff12 S. proliﬁcans M/60 Lung Dissemination Autopsy: lung, kidney,
spleen, CNS, myocardium
Proven Death
8 Busaba13 P. boydii M/44 External
auditory canal
Osteomyelitis
of temporal
bone,
mastoiditis
Biopsy Proven Survival; latest
follow-up visit 2
month later
9 Montero14 P. boydii M/33 CNS
Brain abscesses
CNS: basal
ganglia, pons,
subependymal
Autopsy: CSF, brain tissue Proven Death after 6 days
10 Gonzalez15 S. proliﬁcans M/43 Fungemia Blood Proven Death
11 Horton16 P. boydii M/44 Sphenoid sinus
Sinusitis
Epidural
empyema
of unknown
origin
Necrotic debris of the sinus Colonization Death of unknown
causes, most likely
after non-proven
fungal infection
12 Eckburg17 S. apiospermum M/21 Ear
Mastoiditis
Pulmonary
disease
Biopsy Proven Death by worsening
pulmonary disease
13 Slack18 S. apiospermum M/10 Ear
Otitis media
Pansinusitis,
mastoiditis
Biopsy granuloma external
ear canal
Proven Survival
14 Rollot19 S. apiospermum F/29 Lung (fungus ball) Lung tissue Colonization NR
15 (see case
No. 12)
Yao20 S. apiospermum M/21 Ear Otitis externa Sinusitis,
mastoiditis,
pneumonia
Granulation tissue from
mastoid, nasal cavity
Proven Death probably
to AIDS
16 Idigoras21
(case 3)
S. proliﬁcans M/28 Disseminated
infection
Dissemination Blood, sputum, BAL,
urine, feces (together
with Aspergillus fumigatus)
Proven Death 3
months later
17 Idigoras21
(case 9)
S. proliﬁcans M/30 Lung One sputum sample Colonization Death
18 Idigoras21
(case 10)
S. proliﬁcans M/34 Lung Bronchial aspirate
(repeated); BAL
(together with Aspergillus
fumigatus)
Colonization Death 6 months
later due to
multifocal
leuko-
encephalopathy
19 Del
Palacio22
S. proliﬁcans M/35 Lung Cholecystitis BAL, induced sputum
(together with Pseudomonas
aeruginosa)
Colonization Death after
progressive
abdominal
infection
20 Zaas23 S. apiospermum M/42 Lung (fungus ball) BAL Colonization NR
21 Garcia24 P. boydii F/43 Lung (fungus ball) Transbronchial biopsy Colonization Survival
22 (see case
No. 13)
Abzug25 S. apiospermum M/10 Ear
Otitis media
Bone
destruction of
mastoid
Granuloma external
ear canal
Proven Survival
23 Mazumder26 S. apiospermum F/31 Lung (fungus balls in
multiple cavities)
Pneumothorax Transbronchial biopsy
lung tissue
Proven Survival
24 (see case
No. 23)
Sarva27 S. apiospermum F/31 Lung (fungus ball) Pneumothorax,
left side
Tissue left lower lobe Proven Survival
25 Tammer
(current
case)
S. apiospermum F/31 Multiple cerebral
abscesses
Multiple
cerebral lesions,
pneumonia
Brain biopsy Proven Death
BAL, bronchoalveolar lavage; CNS, central nervous system; CSF, cerebrospinal ﬂuid; NR, not reported.
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Table 2
Laboratory ﬁndings and concomitant diseases
Variable Colonization (n=10/22) Proven IS (n = 12/22)
Dissemination/CNS infection (n=8/12) Localized infection (n=4/12)
CD4+ cell count (cells/ml)
Available data (n) 7/10 4/8 4/4
<50 5 3 2
50–100 0 1 2
100–250 1 0 0
>250 1 0 0
Mean 118 38 34
HIV viral load (mRNA copies/ml)
Available data (n) 2/10 2/8 3/4
<40 0 1 0
>40 2 1 3
Median 32 940 6 020 108 680
White blood cell count (T 109/l)
Available data (n) 2/10 3/8 2/4
Leukocytosis (>12.0  109/l) 0 1 1
Leukopenia (<4.5  109/l) 1 2 1
Normal value 1 0 0
Mean ( 109/l) 3.9 6.2 10.0
Neutrophil cell count (T 109/l)
Available data (n) 4/10 2/8 1/4
<0.5 1 0 0
>0.5 3 2 1
Mean 1.53 2.75 -
AIDS-related diseases
Kaposi’s sarcoma/lymphoma 2 3 0
Pneumocystis jirovecii pneumonia 3 2 2
Herpesviridae reactivationa 3 6 1
Mycobacterium spb 2 0 2
Cryptococcal disease 0 0 1
Candida infection/colonization 3 4 1
Aspergillus infection/colonization 0 1 2
Toxoplasma encephalitis 0 1 1
Bacterial infection 2 2 3
Chronic hepatitis B/C 5 1 3
Co-infection rate (subgroups) 2.0 2.0 1.6
IS, invasive scedosporiosis; CNS, central nervous system.
a Herpesviridae= cytomegalovirus, herpes simplex virus type 1/2, varicella zoster virus.
b Mycobacterium sp=M. tuberculosis, M. avium-intracellulare.
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three of the cases with a proven IS fungal infection was the ﬁrst
manifestation of the HIV disease. All patients with proven IS died.
Fifteen cases were reported since the introduction of HAART.
Among themwere eight patientswith proven IS and seven patients
who were colonized. For two patients the detection of Pseudal-
lescheria/Scedosporium sp guided to the diagnosis of AIDS. Of the
eight patients with proven IS, three responded to therapy.
Antifungal treatment regimes (Table 4) were administered to
nine of the 12 AIDS patients suffering from proven IS owing to the
isolation of Pseudallescheria/Scedosporium species from a clinical
specimen (75%). Five of these patientswere treatedwith antifungalTable 3
Antifungal treatment and clinical outcome
Antifungal treatment regime Antifungal
drugs alone
Antifungal
drugs+ surgery
No antifungal
treatment
Colonization (n=10) 4 4 2
Fatal outcome 1 0 0
Survivor 1 1 1
Other cause of death 1 2 1
Outcome not recorded 1 1 0
Proven IS (n=12) 5 4 3
Fatal outcome 4 1 3
Survivor 1 2 0
Other cause of death 0 1 0
IS, invasive scedosporiosis.agents alone and four underwent surgery in addition to
antimycotic therapy. No patient was treated with surgery alone.
Three patients died before antifungal treatment could be started.
Granulocyte colony-stimulating factor (G-CSF) was adminis-
tered in three cases, and granulocyte macrophage colony-
stimulating factor (GM-CSF) and interferon-gamma (IFN-g) were
administered in one case each (Table 4).
5. Discussion
Invasive or disseminated infections due to the genera
Pseudallescheria/Scedosporium have been reported in immunocom-
petent and in immunocompromised patients.28–32 HIV infection
per se has not been considered a major risk factor for mould
infection, because the innate host defense is impaired only in the
late stage of AIDS disease. Risk factors associated with the
identiﬁcation of Aspergillus sp in respiratory specimens from
HIV-seropositive individuals have been found to be neutropenia, a
CD4+ count <30 cells/ml, corticosteroid use, and Pneumocystis
jirovecii infection.33 Since members of the P. boydii complex and S.
proliﬁcans show virulence and clinical spectra similar to those of
Aspergillus species, similar risk factors could be suggested.34 At the
time point of diagnosis of IS in our patient, her CD4+ cell count was
<30/ml and the treatment regime of TE included corticoids.
Reviewing the published cases, CD4+ counts <50/ml did not differ
signiﬁcantly between colonized and infected individuals. Never-
theless, patients with proven IS showed lower mean CD4+ cell
Table 4
Treatment regimes (available data)
Treatment regime Colonization
(n = 10/22)
Proven IS (n = 12/22)
Dissemination/
CNS infection
(n = 8/12)
Localized
infection
(n = 4/12)
Antifungal treatment
Antifungal drugs alone 4 4 1
Antifungal drugs + surgery 4 1 3
Surgery alone 0 0 0
No antifungal treatment 2 3 0
Immune augmentation
G-CSF 1 1 1
GM-CSF 0 0 1
Interferon-g 0 0 1
Antiretroviral therapy 2 2 3
Immunosuppressive therapy
Corticosteroids 1 3 1
Additional therapy
Antibiotic 4 5 4
Antiviral 4 2 0
Antiparasitic
(Toxoplasma, PjP)
0 5 0
Prophylaxis
Anti-Toxoplasma/PjP 3 0 1
Antifungal (ﬂuconazole) 3 1 1
IS, invasive scedosporiosis; CNS, central nervous system; G-CSF, granulocyte colony
stimulating factor; GM-CSF, granulocyte macrophage colony stimulating factor;
PjP, Pneumocystis jirovecii pneumonia.
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colonized by Pseudallescheria/Scedosporium species.
Corticosteroids have a profound effect on the distribution and
function of neutrophils, monocytes, and lymphocytes and are
therefore reported to be associated with an increased risk of
invasive aspergillosis in allogeneic hematopoietic stem cell
transplant (HSCT) recipients.35 In addition, in vitro investigations
have shown that corticosteroids directly stimulate the growth of
Aspergillus fumigatus, an effect not demonstrated for Pseudal-
lescheria/Scedosporium species so far.36 Previous corticosteroid
treatment did not seem to inﬂuence the acquisition of Pseudal-
lescheria/Scedosporium sp as it was administered in only four of the
12 patients with subsequent development of proven IS. Flucona-
zole prophylaxis given after cryptococcal disease did not prevent
other mould infections like IS because ﬂuconazole is ineffective
against Pseudallescheria/Scedosporium species.
Analysis of the cases regarding the gender distribution showed
a marked preponderance of males over females, resulting in a
male/female ratio of 5:1 for patients with proven IS. Interestingly,
Mylonakis et al.,37 who analyzed 342 cases of pulmonary
aspergillosis in AIDS patients, observed a male/female ratio of
4.9:1. As the gender distribution of HIV disease in Europe and
Northern America is approximately 3:1,38 a predisposition for the
male is suggested.
Members of the P. boydii complex are ubiquitously distributed
in soil and water, whereas S. proliﬁcans is primarily isolated from
soil and plants.39 Furthermore, S. proliﬁcans is geographically more
restricted than members of the P. boydii complex. Thus, members
of the P. boydii complex were more common in patients with
advancedHIV disease as compared to S. proliﬁcans. The origin of the
patients colonized or infected by S. proliﬁcans correlates with
known endemic areas in the northern part of the Iberian Peninsula,
Australia and the USA.22,40 Infections have rarely been reported
from other countries.41,42
Filamentous fungi enter the respiratory tract via inhalation; the
skin, wounds, and eyes are infected by direct inoculation.43 The
respiratory tract, including the lung, was the most frequently
reported portal of entry for Pseudallescheria/Scedosporium sp in
patients with advanced HIV disease. Interestingly, members of theP. boydii complex infected the host either via the respiratory tract
or the external auditory canal, whereas S. proliﬁcans exclusively
infected the lung. In our patient, the mode of entry remains
unclear. Small foci can be unapparent during the initial stages of
the infection and may not be detected by radiographic means.44
Similar observations have been described by Nenoff et al.,12 as
chest radiographs revealed no signs of pulmonary inﬁltration, but
autopsy showed mycotic inﬁltrates in the left upper lobe of the
lung.
In persons exposed to a high environmental inoculum of spores
and with underlying pulmonary diseases, transient airway
colonization may become persistent. Colonization of the respira-
tory tract due to S. apiospermum and S. proliﬁcans was extensively
evaluated in cystic ﬁbrosis patients and in liver transplant
recipients.22,45 Our review shows that colonization of the airway
tract is not a rare event in AIDS patients. Interestingly, fungus ball
formation in AIDS patients was exclusively caused by members of
the P. boydii complex, although the lack of cases with fungus ball
formations by S. proliﬁcans may be due to the limited number of
case reports. Nevertheless, in contrast to Aspergillus species, the
role of members of the P. boydii complex or S. proliﬁcans as airway
colonizers is not well accepted and the risk for the development of
invasive or disseminated diseases should not be underestimated,
especially when the immune system is impaired, as was
demonstrated in case 23.26,27 Thus, colonized patients with
underlying immune diseases should be subjected to regular
follow-up evaluations.
As illustrated in our case, CNS involvement represents a
devastating complication of pseudallescheriosis/scedosporiosis.
The species are frequently reported to exhibit a particular tropism
for the CNS, but the mechanisms of the host defense evasion and
damage of the blood–brain barrier remain largely unexplained.46–
50 In this study, CNS manifestations were observed in 41.7% of the
AIDS patients with proven IS. Since the rate of dissemination in
previously healthy patients, for example after near-drowning, is
similar to the data presented here, immunosuppression appears
not to be a precondition for CNSmanifestations.51–53In our patient,
TE was suspected based on typical contrast-enhancing masses in
the MRI, neurological symptoms, seropositivity for Toxoplasma-
speciﬁc IgG antibodies, and initial remission of clinical symptoms
after administration of antiparasitic therapy. Since similar lesions
of different size were the most common ﬁnding reported from CNS
infections due to members of the P. boydii complex,54 a computed
tomography (CT)-guided needle biopsy at the ﬁrst time of
deterioration would have been required to conﬁrm the diagnosis
in our patient.
Mimicking the clinical features of certain other important
ﬁlamentous fungi, Pseudallescheria/Scedosporium species cannot be
distinguished from others by the use of histological methods
exclusively. Therefore, rapid identiﬁcation of the infectious
organism by molecular methods in parallel to cultures is
mandatory and necessary due to the poor response of the species
to amphotericin B.47,55,56
Mortality rates after invasive fungal infection are high,
especially in patients with disseminated infections. In this study
we calculated amortality rate of 75% for AIDS patients with proven
IS. Similar results were reported for P. boydii infections in solid
organ transplant recipients.57 Moreover, the mortality rates
differed with respect to the causative agent. Fatality rates of
invasive infections due to S. proliﬁcans were 100% compared with
75% for infections caused bymembers of the P. boydii complex. In a
study reviewing German S. proliﬁcans cases, 92% of the patients
developed a fatal infection.58 The high fatality rate of S. proliﬁcans
infectionsmay be caused by two facts: (1) conidia containmelanin
which has been related to the high afﬁnity to the brain and (2) the
species is multidrug-resistant.59
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resistant to amphotericin B and terbinaﬁne. As Aspergillus species
are known to be the most common cause of fungal infections,
amphotericin B is often used as ﬁrst-line therapy. It is therefore
important to distinguish Aspergillus species from Pseudallescheria/
Scedosporium sp in order to initiate an appropriate antifungal
treatment. Miconazole and voriconazole have shown low MIC
values against themembers of the P. boydii complex.60,61 Today the
intravenous administration of miconazole is limited by its high
toxicity and in Germany by its unavailability. Voriconazole is
accepted as the gold standard because it has been used successfully
in the treatment of CNS infections due to members of the P. boydii
complex.62 The clinical experience with posaconazole against
Pseudallescheria/Scedosporium sp is limited and this needs further
investigation.
In the presented case, voriconazole was combined with
caspofungin. New echinocandins lack CNS penetration, an effect
also known from amphotericin B. The combination of caspofungin
with voriconazole signiﬁcantly reduced colony counts in lung,
liver, kidney and brain tissues in experimental invasive aspergil-
losis in neutropenic guinea pigs, suggesting a penetration of the
drugs into the CNS via the impaired blood–brain barrier.63 For S.
proliﬁcans, synergistic effects of voriconazole with terbinaﬁne have
been observed.58,64–66 In our case study, no AIDS patient with S.
proliﬁcans infection was treated with a combination of terbinaﬁne
plus azole, suggesting that this treatment option is not well
established.
Multiple studies have conﬁrmed the beneﬁcial effect of
additional radical surgical debridement to reduce fungal bur-
den.46,47,67 This review demonstrates differences between the
mortality rate of patients treated with antifungal drugs alone and
those treated with antifungal drugs plus surgery. Similar
observations have been reported by Kantarcioglu et al.54
In this study, only three of the AIDS patients with proven IS
responded to therapy. In all cases the infections remained localized.
All patients were infected with members of the P. boydii complex.
Two non-neutropenic patients underwent radical surgery plus
antimycotic treatment. The other survivor did not undergo surgery
but was additionally treated with a complex immune-enhancing
regime (G-CSF, IFN-g, GM-CSF). HAART was administered in two
patients. The small number of successful clinical outcomes from
deep-seated S. proliﬁcans infections supported the efﬁcacy of
voriconazole plus terbinaﬁne with or without surgery and a
supportive immune-enhancing therapy.64–66,68
The introduction of HAART in 1996 has signiﬁcantly reduced
the rates of opportunistic infections. However, most of the proven
cases of pseudallescheriosis/scedosporiosis in this review were
reported after 1996 (eight vs. four cases).
It has been reported that the receipt of HAART is associatedwith
immune reconstitution disease (IRD) or inﬂammatory syndrome
(IRIS) in approximately 32% of patients.69 Due to a lack of
information in the reviewed cases we cannot comment on the
occurrence of IRIS. For most of the cases, data on the pre- and post-
HAART CD4+ cells and HIV-RNA copies were not available.
In our case, an unusual course of the suggested TE could not be
excluded. The patientwas naı¨ve to ART at the time of diagnosis. She
responded well to HAART, resulting in a rapid decrease in the HIV-
1 RNA level and a rise in the CD4+ cell count. Thus it remains
unclear whether HAART obscured an existing scedosporiosis, or if
this infection was acquired secondary to other opportunistic
infections like TE.
6. Conclusions
Members of the P. boydii complex and S. proliﬁcans should be
considered in the differential diagnosis as potential causes ofinfections in patients with advanced HIV disease. Since cerebral
lesions may be caused by various pathogens or by the HIV disease
itself, the rapid differentiation between HIV-associated diseases
and opportunistic infections is a prerequisite for a successful
target-related treatment. Stereotactic CT-guided needle biopsy as
early as possible is the most suitable approach to conﬁrm the
diagnosis. Serological methods to detect scedosporiosis are not
available. Histological examination is necessary to differentiate
between colonization and invasive infection, but is unsuitable to
identify the fungus. Microbiological investigation, including
culture and molecular methods, is indispensable for a correct
diagnosis and to initiate an adequate therapy. Radical surgery,
wherever applicable, combined with a target-related antimycotic
chemotherapy (voriconazole plus terbinaﬁne in the case of S.
proliﬁcans infections; voriconazole plus caspofungin against
members of the P. boydii complex) and adjunct immune
stimulation advance the clinical outcome.
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